Business
Genflow Signs CDAs with Animal Health Companies
Genflow Biosciences PLC announced on September 15, 2025, the signing of two Confidential Disclosure Agreements (CDAs) with leading animal health companies. These agreements aim to facilitate data exchange and discussions regarding potential collaborations, leveraging Genflow's SIRT6-centenarian gene therapy platform for both human and animal health. This development builds upon the company's ongoing GF-1004 Dog Aging study, which has reported no adverse events. The collaborations seek to extend healthspan and improve the quality of life for companion animals, targeting a rapidly growing market. These partnerships could accelerate revenue generation and market penetration by unlocking global scale, regulatory expertise, and commercial infrastructure. Disclaimer*
About this update from Genflow Biosciences Plc
[{"type":"text","content":"\n\n \n \n15, September 2025\n \nGenflow Biosciences Plc \n \nGenflow Signs CDAs with Animal Health Companies to Advance Longevity Gene Therapy Platform\n \nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), the only publicly listed longevity company in Europe, today announces that it has signed two Confidential Disclosure Agreements (CDAs) with leading animal health companies to facilitate the exchange of data and initiate discussions on potential collaborations.\n \nThese CDAs mark an important milestone in Genflow's strategy to leverage its proprietary SIRT6-centenarian gene therapy platform for both human and animal health. Building on the Company's ongoing GF-1004 Dog Aging (beagle) study which has reported no adverse events to date. The agreements will provide a framework for evaluating partnership opportunities aimed at extending healthspan and improving quality of life in companion animals, a rapidly growing and high-value market segment.\n \nStrategic Rationale\nGenflow's first-in-class science, when combined with the resources of a large pharmaceutical partner, offers a faster path to commercialization therefore, derisking execution and maximizing shareholder value. Through such collaborations, Genflow can also unlock global scale, regulatory expertise, and commercial infrastructure more quickly accelerating both revenue generation and market penetration.\n \nDr. Eric Leire, CEO of Genflow, commented: \"The signing of these CDAs reflects strong industry interest in our longevity platform and represents a further step toward building strategic partnerships in animal health. As we continue to advance GF-1004 in our canine trial, engaging with major animal health players will strengthen our pathway to potential licensing agreements and future commercialization.\"\n \nContacts\n\n\n\n\nGenflow Biosciences\n\n\nHarbor Access \n\n\n\n\nDr Eric Leire, CEO\n\n\nJonathan Paterson, Investor Relations\n\n\n\n\n+32-477-495-881\n\n\n+1 475 477 9401\n\n\n\n\n\n\n\[email protected]\n\n\n\n\n \n\n\n\n\nCorporate Brokers\n\n\n\n\n\n\n\nCapital Plus Partners Ltd\n\n\n\n\n\n\n\nJon Critc...